Biophan to Present at 2004 Medical Device Forum in New York City on January 15.Business Editors/Health/Medical Writers BIOWIRE2K ROCHESTER, N.Y.--(BUSINESS WIRE)--Jan. 12, 2004 Biophan Technologies, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BIPH BIPH Bogomoletz Institute of Physiology (National Academy of Sciences; Ukraine) ) today announced its selection for the final line-up of presenting companies at the 2004 Leadership Forum on Medical Devices, which takes place in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. on January 15, 2004. "We are very pleased and appreciative to have been invited to participate in this event as one of the four invited companies," stated Michael Weiner, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Biophan Technologies, Inc. The forum will be hosted by Mr. Olle Wastberg, Consul General of Sweden in New York, and will take place at his residence at 600 Park Avenue. It will offer a broad overview of the international medical device industry as well as in-depth analysis of some of the upcoming new technologies in this field. The conference is co-sponsored by Podholding, Elekta, Inc., and ISA. Forty-five specially invited industry executives, investors, analysts and representatives of business media are invited to attend. For further information, please visit http://www.biophan.com/meddevforum04.html. About Biophan Technologies, Inc. Biophan Technologies develops and markets cutting-edge technologies used to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tool--safe and compatible with magnetic resonance imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. (MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. ) equipment. Committed to growth through innovation and developmental leadership, Biophan's management holds exclusive licenses for four issued U.S. patents and has filed 51 related patents that will help establish Biophan products as the standard of care in each of their markets. For more information, please visit www.biophan.com. Biophan Technologies is also listed on the Frankfurt Stock Exchange Frankfurt Stock Exchange The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. (FSE FSE 1. feline spongiform encephalopathy. 2. focal symmetrical encephalomalacia. : BTN BTN In currencies, this is the abbreviation for the Bhutan Ngultrum. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ). Cautionary Statement Regarding Forward-Looking Statements Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion